Beyondspring Inc (BYSI)
NASDAQ:BYSI
Want to see BYSI full AI Analyst Report?
BYSI Stock Chart & Stats
$1.66
-$0.09(-5.17%)
At close: 4:00 PM EST
$1.66
-$0.09(-5.17%)
Day’s Range― - ―
52-Week Range$1.18 - $3.44
Previous CloseN/A
Volume3.10K
Average Volume (3M)478.07K
Market Cap
$64.56M
Enterprise Value$60.77M
Total Cash (Recent Filing)$7.86M
Total Debt (Recent Filing)$246.00K
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Sep 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding41,119,820
10 Day Avg. Volume1,393,566
30 Day Avg. Volume478,066
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.20K
Enterprise Value/Ebitda-7.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)$194.65M
Bulls Say, Bears Say
Bulls Say
Focused Oncology PipelineBeyondSpring's focused clinical-stage pipeline centers on Plinabulin for chemotherapy-induced neutropenia and combination immuno-oncology use. A clear, specialized R&D thesis increases partnership and licensing appeal, and aligns the company with durable oncology demand if late-stage trials succeed.
Improving Loss & Cash Flow TrendReported net losses have meaningfully narrowed from roughly $60–64M in earlier years to single-digit/low-double-digit ranges recently, reflecting lower operating burn. Improving loss and operating cash trends extend runway and increase strategic optionality for partnerships or orderly financings.
Low Nominal Debt BurdenStated leverage is modest in absolute dollars, limiting fixed interest and covenant pressures. Low nominal debt reduces near-term cash outflows for financing costs, giving management flexibility to allocate limited resources to trials and partner discussions without large debt servicing constraints.
Bears Say
Pre-commercial, No RevenueThe company remains pre-commercial with effectively no recurring revenue, leaving operating performance entirely dependent on clinical progress and external funding. Lack of commercial cash flow materially reduces earnings visibility and heightens execution risk over the medium term.
Negative Shareholder Equity & Shrinking AssetsShareholder equity turned negative and assets have contracted substantially, signaling sustained cash consumption and balance sheet erosion. This structural weakness constrains financing alternatives, increases dilution risk, and weakens the firm's capacity to absorb setbacks in trials or operations.
Persistent Cash Burn & Funding DependenceOperating cash flows have been negative annually and free cash flow remains consistently deficient, necessitating external capital to sustain trials. Ongoing burn creates a durable financing overhang that can force dilutive financings or unfavorable deals, limiting long-term strategic flexibility.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $1.18 and its highest was $3.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $64.56M.
When is Beyondspring Inc’s upcoming earnings report date?
Beyondspring Inc’s upcoming earnings report date is Sep 04, 2026 which is in 101 days.
How were Beyondspring Inc’s earnings last quarter?
Beyondspring Inc released its earnings results on May 13, 2026. The company reported -$0.052 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.052.
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Beyondspring Inc reported an EPS of -$0.052 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.317%.
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyondspring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Technical Analysis
Plus Therapeutics
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Ownership Overview
10.96% Insiders
2.11% Mutual Funds
9.38% Other Institutional Investors
75.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---